REGN3500

anti-IL-33 monoclonal antibody · Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for REGN3500, covering 2017-11-08 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

See pricing